Possible harms and precautions caused by taking rasagiline (Azila)

1. Drug overview and clinical application

Rasagiline (Rasagiline) is a selective monoamine oxidaseB inhibitor (MAO-B inhibitor Preparations), mainly used for monotherapy of Parkinson's disease (PD) or as adjuvant treatment of levodopa (Levodopa). Its mechanism of action is to improve the motor symptoms of patients with Parkinson's disease by inhibiting the degradation of dopamine in the brain and increasing the concentration of dopamine in the synaptic cleft. Rasagiline is generally well tolerated clinically, but its drug characteristics determine that there are still certain risks during use, which requires the joint attention of patients and doctors.

2. Main possible harms

1.Cardiovascular risks: Rasagiline may cause increased blood pressure or arrhythmia, especially in patients with high blood pressure, heart disease, or taking other drugs that affect the cardiovascular system. Some patients may experience mild palpitations, dizziness, or blood pressure fluctuations early in treatment.

2. Central nervous system side effects: Common ones include insomnia, headache, anxiety, dizziness and occasional hallucinations or delusions. For elderly patients or those with cognitive impairment, central nervous system side effects may be more prominent and require close monitoring.

3.Drug interaction risk: The use of rasagiline with other MAO inhibitors, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), etc. may cause serotonin syndrome, which is characterized by psychosis, high fever, increased muscle tone and autonomic nervous system dysfunction.

4.Digestive system discomfort: Some patients may experience nausea, vomiting, constipation or loss of appetite. Most of these side effects are mild to moderate, but they still require attention, especially in elderly patients, which may affect nutritional intake.

3. Precautions before and during use

1.Pre-medication assessment: Before starting rasagiline treatment, the patient's cardiovascular status, liver and kidney function, and previous drug use history need to be assessed. For patients with severe heart disease or unstable blood pressure, the dosage should be adjusted with caution or under the guidance of a professional physician.

2.Avoid drug conflicts: Patients need to inform their doctors about all the drugs they are taking, including prescription drugs, over-the-counter drugs and health care products, and avoid taking them with MAO inhibitors, certain antidepressants or combination drugs containing caffeine and stimulants to reduce the risk of serious drug interactions.

3.Dosage and timing: Rasagiline is usually taken orally once daily, preferably at a fixed time to maintain stable blood concentrations. Dosage adjustment must be strictly in accordance with the doctor's instructions and avoid increasing or decreasing the dose on your own.

4.Monitoring and follow-up: Blood pressure, heart rate and central nervous system status need to be monitored regularly during medication. Patients or family members should record uncomfortable symptoms, such as worsening insomnia, hallucinations or abnormal heart palpitations, and report them to the doctor in a timely manner.

4. Special groups and individualized management

1. Elderly patients: The elderly are more sensitive to the side effects of rasagiline on the central nervous system and may experience falls, decreased attention, or fluctuations in cognitive function. They should be carefully observed and the dosage should be adjusted appropriately.

2. Patients with hepatic insufficiency: Rasagiline is mainly metabolized by the liver, and abnormal liver function may lead to drug accumulation and increased side effects. Doctors often adjust the dose or extend the interval between doses based on liver function assessment.

3.Combined medication strategy: Parkinson’s disease patients are often accompanied by multiple chronic diseases and need to take multiple medications at the same time. Individualized medication regimens can balance efficacy and risks. For example, when combined with levodopa, care should be taken to avoid blood pressure fluctuations or motor complications caused by excessive doses.

5. Countermeasures and safety suggestions

1. Mild side effects occur: such as mild insomnia, dizziness or nausea, which can be alleviated by adjusting the medication time, taking it with meals or lifestyle intervention.

2. If serious adverse reactions occur: such as sharp increase in blood pressure, sustained arrhythmia or mental abnormality, the drug should be stopped immediately and seek medical treatment.

3.Regular review: It is recommended to review cardiovascular indicators and liver function every 3~6 months, and combine neurological follow-up to evaluate efficacy and safety when necessary.

4.Education and self-management: Patients and their families should understand the characteristics and potential risks of drugs, record drug reactions, communicate abnormal situations in a timely manner, and improve drug safety.

Rasagiline (Rasagiline) has a significant effect on improving motor symptoms in the treatment of Parkinson's disease, but it still has potential hazards such as cardiovascular, central nervous system and drug interactions. Through scientific pre-medication assessment, regular monitoring, individualized dose adjustment and patient education, risks can be minimized and both efficacy and safety can be ensured. Patients and their families need to work closely with their doctors, follow the follow-up plan, reasonably manage side effects, and achieve long-term and stable Parkinson's disease treatment effects.

Reference link:https://www.drugs.com